Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.4 INR -1.54% Market Closed
Market Cap: 484.9m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Intrinsic Value

526139 doesn't have a meaningful market cap.
TRABI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one TRABI stock under the Base Case scenario is 0.28 INR. Compared to the current market price of 6.4 INR, Transgene Biotek Ltd is Overvalued by 96%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TRABI Intrinsic Value
0.28 INR
Overvaluation 96%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Transgene Biotek Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TRABI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TRABI?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Transgene Biotek Ltd

Provide an overview of the primary business activities
of Transgene Biotek Ltd.

What unique competitive advantages
does Transgene Biotek Ltd hold over its rivals?

What risks and challenges
does Transgene Biotek Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Transgene Biotek Ltd.

Provide P/S
for Transgene Biotek Ltd.

Provide P/E
for Transgene Biotek Ltd.

Provide P/OCF
for Transgene Biotek Ltd.

Provide P/FCFE
for Transgene Biotek Ltd.

Provide P/B
for Transgene Biotek Ltd.

Provide EV/S
for Transgene Biotek Ltd.

Provide EV/GP
for Transgene Biotek Ltd.

Provide EV/EBITDA
for Transgene Biotek Ltd.

Provide EV/EBIT
for Transgene Biotek Ltd.

Provide EV/OCF
for Transgene Biotek Ltd.

Provide EV/FCFF
for Transgene Biotek Ltd.

Provide EV/IC
for Transgene Biotek Ltd.

Compare the intrinsic valuations
of Transgene Biotek Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Transgene Biotek Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Transgene Biotek Ltd compared to its peers.

Compare the P/E ratios
of Transgene Biotek Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Transgene Biotek Ltd with its peers.

Analyze the financial leverage
of Transgene Biotek Ltd compared to its main competitors.

Show all profitability ratios
for Transgene Biotek Ltd.

Provide ROE
for Transgene Biotek Ltd.

Provide ROA
for Transgene Biotek Ltd.

Provide ROIC
for Transgene Biotek Ltd.

Provide ROCE
for Transgene Biotek Ltd.

Provide Gross Margin
for Transgene Biotek Ltd.

Provide Operating Margin
for Transgene Biotek Ltd.

Provide Net Margin
for Transgene Biotek Ltd.

Provide FCF Margin
for Transgene Biotek Ltd.

Show all solvency ratios
for Transgene Biotek Ltd.

Provide D/E Ratio
for Transgene Biotek Ltd.

Provide D/A Ratio
for Transgene Biotek Ltd.

Provide Interest Coverage Ratio
for Transgene Biotek Ltd.

Provide Altman Z-Score Ratio
for Transgene Biotek Ltd.

Provide Quick Ratio
for Transgene Biotek Ltd.

Provide Current Ratio
for Transgene Biotek Ltd.

Provide Cash Ratio
for Transgene Biotek Ltd.

What is the historical Revenue growth
over the last 5 years for Transgene Biotek Ltd?

What is the historical Net Income growth
over the last 5 years for Transgene Biotek Ltd?

What is the current Free Cash Flow
of Transgene Biotek Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Transgene Biotek Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Transgene Biotek Ltd

Current Assets 11.1m
Cash & Short-Term Investments 77k
Receivables 84k
Other Current Assets 10.9m
Non-Current Assets 1.4B
Long-Term Investments 950k
PP&E 16.7m
Intangibles 65.5m
Other Non-Current Assets 1.3B
Current Liabilities 111.4m
Accounts Payable 2m
Short-Term Debt 89.2m
Other Current Liabilities 20.2m
Non-Current Liabilities 1.2B
Long-Term Debt 50.8m
Other Non-Current Liabilities 1.2B
Efficiency

Earnings Waterfall
Transgene Biotek Ltd

Revenue
1.8m INR
Cost of Revenue
-5.4k INR
Gross Profit
1.8m INR
Operating Expenses
-11.8m INR
Operating Income
-10m INR
Other Expenses
6.8m INR
Net Income
-3.2m INR

Free Cash Flow Analysis
Transgene Biotek Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TRABI Profitability Score
Profitability Due Diligence

Transgene Biotek Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 1-Year Revenue Growth
ROE is Increasing
42/100
Profitability
Score

Transgene Biotek Ltd's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

TRABI Solvency Score
Solvency Due Diligence

Transgene Biotek Ltd's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Average D/E
Short-Term Solvency
Positive Net Debt
26/100
Solvency
Score

Transgene Biotek Ltd's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TRABI Price Targets Summary
Transgene Biotek Ltd

There are no price targets for TRABI.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TRABI?

Click here to dive deeper.

Dividends

Transgene Biotek Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for TRABI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Transgene Biotek Ltd Logo
Transgene Biotek Ltd

Country

India

Industry

Biotechnology

Market Cap

484.9m INR

Dividend Yield

0%

Description

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Contact

TELANGANA
Medak
Plot 68, 69 & 70, IDA Bollaram, ANRICH Industrial Area, IDA Bollaram
+914065589499
www.transgenebiotek.com

IPO

1992-09-23

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one TRABI stock?

The intrinsic value of one TRABI stock under the Base Case scenario is 0.28 INR.

Is TRABI stock undervalued or overvalued?

Compared to the current market price of 6.4 INR, Transgene Biotek Ltd is Overvalued by 96%.

Back to Top